Prevalence of Dyschromatopsia in Glaucoma Patients

Status Withdrawn

Clinical Trial Summary

Glaucoma is a progressive disease resulting in loss of retinal nerve cells and their axons (retinal nerve fibers). Retinal nerve fibers are ordered in a special manner when they enter the optic nerve. Hence, damage to the retinal nerve fibers by glaucoma results in visual field defects at certain locations. Furthermore, the retinal nerve fiber layers from different receptors for different colors are ordered in a special manner as well. Thus, it is possible that glaucomatous damage causes color vision dysfunction (dyschromatopsia).

At the moment there is disagreement whether dyschromatopsia occurs at early- to mid-stage or only in end-stage glaucoma.

By testing color vision in glaucoma patients the prevalence of dyschromatopsia in glaucoma and in different stages of the disease will be investigated.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01994564
Study type	Observational
Source	Massachusetts Eye and Ear Infirmary
Contact
Status	Withdrawn
Phase	N/A
Start date	November 2012
Completion date	January 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03284853` - Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension	Phase 3
Terminated	`NCT03611530` - CoQun Study - (COQUN): a Study to Evaluate the Effects of CoQun in Patients Affected by Open-angle Glaucoma	N/A
Not yet recruiting	`NCT06441643` - Next Generation Rocklatan	Phase 2
Not yet recruiting	`NCT02868502` - Different Glaucoma Treatments Effect on Intraocular Pressure Fluctuation With Postural Change in Eyes With Open-angle Glaucoma	N/A
Completed	`NCT02272569` - STARflo European Safety and Efficacy Study	N/A
Completed	`NCT02628223` - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma	N/A
Completed	`NCT01936389` - A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma	Phase 2
Completed	`NCT00941525` - Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure	Phase 4
Completed	`NCT00539526` - Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues	Phase 4
Completed	`NCT00121147` - Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan	N/A
Active, not recruiting	`NCT05035394` - Swedish Microinvasive Glaucoma Surgery Study (SMIGS)	N/A
Completed	`NCT03450629` - Evaluation of Safety and Efficacy of PDP-716	Phase 3
Active, not recruiting	`NCT06061718` - Travoprost Intraocular Implant in Conjunction With Cataract Surgery	Phase 3
Recruiting	`NCT05241938` - PSLT Compared to Prostaglandin Analogue Eye Drops	N/A
Completed	`NCT01342406` - Effects of Selective Laser Trabeculoplasty on Aqueous Humor Dynamics
Completed	`NCT02250612` - SYL040012, Treatment for Open Angle Glaucoma	Phase 2
Completed	`NCT01937312` - Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue	Phase 4
Completed	`NCT01937299` - Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®	Phase 4
Terminated	`NCT01983579` - TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection	Phase 4
Completed	`NCT01229982` - A Study Evaluating the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma	Phase 2